The safe and effective use of tofacitinib and ustekinumab combination therapy in infantile onset inflammatory bowel disease
JPGN Reports · 2026-11 · 7 (4) · 544-549
DOI: 10.1002/jpr3.70190 ↗Kurz gefasst
Fachartikel in der Zeitschrift JPGN Reports, online erschienen am 27.04.2026. Verfasst von Smridhi Mahajan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Allergy and Immunology The University of Texas Southwestern Medical Center Dallas Texas USA. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Infantile‐onset inflammatory bowel disease (IOIBD) is a rare and severe subset of very‐early‐onset IBD, often associated with immune dysregulation and poor response to conventional therapies. Data regarding the use of Janus kinase inhibitors (JAKI) in this population is limited. We conducted a retrospective chart review of four patients treated with tofacitinib in combination with ustekinumab after failing multiple agents at a tertiary referral center. All four patients demonstrated clinical, laboratory, and endoscopic remission. No adverse events were observed. Genetic evaluation did not reveal monogenic causes in any of these patients. These findings suggest that JAKI may represent a safe and effective therapeutic option for carefully selected patients with difficult‐to‐treat IOIBD, either as a bridge to or in combination with ustekinumab. Larger prospective studies are warranted to better define the role of JAKI in this challenging patient population.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Allergy and Immunology The University of Texas Southwestern Medical Center Dallas Texas USA.
- Department of Pediatric Gastroenterology The University of Texas Southwestern Medical Center Dallas Texas USA.
ORCID-Profile: Smridhi Mahajan
Zitieren
APA
Mahajan, S., Wysocki, C., & Gurram, B. (2026). The safe and effective use of tofacitinib and ustekinumab combination therapy in infantile onset inflammatory bowel disease. JPGN Reports, 7(4), 544-549. https://doi.org/10.1002/jpr3.70190
Vancouver
Mahajan S, Wysocki C, Gurram B. The safe and effective use of tofacitinib and ustekinumab combination therapy in infantile onset inflammatory bowel disease. JPGN Reports. 2026;7(4):544-549. doi:10.1002/jpr3.70190
BibTeX
@article{Mahajan2026,
author = {Mahajan, Smridhi and Wysocki, Christian and Gurram, Bhaskar},
title = {The safe and effective use of tofacitinib and ustekinumab combination therapy in infantile onset inflammatory bowel disease},
journal = {JPGN Reports},
year = {2026},
volume = {7},
number = {4},
pages = {544--549},
doi = {10.1002/jpr3.70190}
}
EUVIMED